Background {#Sec1}
==========

Approximately 20--50% of hospitalized patients are reported to be malnourished \[[@CR1]\]. The nutritional status of a patient generally declines during hospitalization \[[@CR2], [@CR3]\]. Poor food intake during hospitalization is caused by deterioration of nutritional status, and malnutrition is often associated with complications including infection, increased number of hospital days, and increased mortality \[[@CR1], [@CR4], [@CR5]\]. The American Society of Parenteral and Enteral Nutrition guidelines suggests that patients at risk of malnutrition should be provided with over 80% of their calorie and protein requirements within 2 to 3 days \[[@CR6]\]. Patients with sarcopenia imbalance generally have a lower 5-year survival rate in cancer patients \[[@CR7]\]. The quality of protein intake is important for the recovery of the immune system, physical strength, and wound healing after surgery; this is problematic since the patient's protein intake is generally quite poor \[[@CR8]\].

In particular, patients who undergo a pancreatectomy or hepatectomy usually have a severe imbalance in their nutritional status due to the disruption of digestive function and nutritional absorption postoperatively. Therefore, it is necessary to use high-quality protein-derived foods that can effectively increase protein intake. The United Nations Food and Agriculture Organization (FAO) is actively encouraging food production of edible insects as a new food source for the future. Currently, various insects are used in food in many regions, including Africa, Asia, South America, and Australia. The edible insects are high in protein content (50--60%) and contain a large amount of fat, fiber, vitamins, and minerals. *Tenebrio molitor* (mealworm), which is an edible insect, contains a large amount of protein and unsaturated fatty acid. The nutritional components of these mealworm are thought to be of value as nutrient sources of high quality in a small amount of patients who need high nutrition.

The purpose of this study is to evaluate the development of long-term personalized products using mealworm and the enhancement of stability, nutritional status and immune status according to ingestion.

Methods/design {#Sec2}
==============

Study design and period {#Sec3}
-----------------------

The trial is a single center, two-armed phase III study. The trial has been registered at [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (NCT03201926). Patients will be recruited by the Pancreatobiliary Cancer Clinic, Gangnam Severance Hospital, Yonsei University College of Medicine. The expected total duration of patient accrual is 2 years and 6 months and the follow-up period is 6 months.

Study objectives and endpoints {#Sec4}
------------------------------

The primary endpoint is to evaluate body cell mass index at 2 months postoperatively. Secondary endpoints include other body composition changes as well as nutrition index and immune function.

Patient selection and enrollment criteria {#Sec5}
-----------------------------------------

### Inclusion criteria {#Sec6}

Patients scheduled for surgery with pancreatobiliary disease and liver cancer (HCC, CCC, and metastatic liver cancer)Karnofsky performance status ≥70Patients who provide informed consent

### Exclusion criteria {#Sec7}

Patients who underwent palliative surgeryPatients with uncontrolled preoperative conditionsPrevious history of surgery affecting nutritional status (ex, gastrectomy, colectomy, etc)Pregnant and lactating womenPatients with an allergy to mealworms

Sample size calculation {#Sec8}
-----------------------

The output of the sample size will be based on an independent two-sample t test. It is expected that there will be a difference in body cell mass between the standard meal group (control) and the group ingesting the mealworms. Assuming an alpha value of 0.05 and 1-β (power) of 0.8, 75 samples will need to be obtained for each group; considering the dropout rate of 10%, 84 samples will need to be obtained for each group. The total of the two groups is 168. The primary endpoint will be the number of subjects and body cell mass. A comparison will then be made between the two groups at 2 months. A subgroup analysis of pancreatobiliary and liver disease will also be performed as a secondary endpoint. Patients with pancreatobiliary and liver disease in our clinic have a 2:1 ratio. Therefore, the 168 patients were divided into two groups: one with 112 patients and the other with 56 patients. Patients with pancreaticobiliary disease (Group A & B) and liver (Group C) disease were assigned through stratified randomization. Pancreatobiliary disease group is divided into enteral feeding group(Group A) and non enteral feeding group.(Group B).

Pretreatment evaluation {#Sec9}
-----------------------

All patients who are potential candidates for hepatopancreatobiliary surgery will undergo a standard evaluation that will include contrast-enhanced computed tomography (CT), endoluminal ultrasound (EUS), magnetic resonance imaging (MRI), and positron emission tomography (PET-CT), which will be discussed at the preoperative conference.

Patients recommended for major hepatopancreatobiliary surgery (such as a liver resection, pancreaticoduodenectomy, or total/distal pancreatectomy) will be contacted and provided with a participant information sheet. Patients will be divided into three groups according to the type of surgery.

Treatment {#Sec10}
---------

### Trial intervention {#Sec11}

Patients receiving dietary supplementation with mealworms after their pancreatectomy, bile duct resection and hepatectomy will be given the mealworms during their hospitalization period and for another 2 months after discharge. The patients in group A will undergo enteral feeding after surgery (for those who undergo a pancreaticoduodenectomy, nutrients will be administered by an enteral feeding tube for early feeding while securing the pancreatojejunostomy). A feeding nasojejunal tube will be placed for patients in the enteral feeding group. Enteral feeding (Newcare 300 RTH, Daesang, Korea) will start within 24 h postoperatively at a rate of 20 mL/h. The velocity will be progressively increased by 20 mL/d until reaching the full nutritional goal (25 kcal/kg). Enteral feeding will be delivered by an infusion pump for 18 h/day with 6 h of rest.

On postoperative day 7, abdominal and pelvic CT scans will be obtained, and if there are no complications, we will then start patients on a clear liquid diet for 1 day. In addition, the patients will be permitted to have a full liquid diet for 2 days and then a soft diet for 3 days following the liquid diet.

The patients of group B will undergo oral feeding 2 days after the surgery. (distal pancreatectomy, total pancreatectomy and bile duct resection) We will start patient's clear liquid diet for 1 day. The patients will be permitted to have a full liquid diet for 2 days and soft diet for 3 days following the liquid diet.

The patients of group C will undergo oral feeding 2 days after surgery (which includes liver resections). We will then start the patients on a clear liquid diet for 1 day. In addition, the patients will be permitted to have a full liquid diet for 2 days and soft diet for 3 days following the liquid diet. The mealworm powder include 3 g of carbohydrate, 14.4 g of protein and 11 g of fat, 163 kcal per 30 g. (Table [1](#Tab1){ref-type="table"}) As a result of a nutritional analysis of mealworm powder, 10.28 g of carbohydrate, 48.26 g of protein and 35.81 g of fat were found per 100 g. In particular, the protein includes essential amino acids as well as many unsaturated fatty acids ranging from 76 to 80% of the total fatty acids. In addition, iron and calcium and other minerals were found (Table [2](#Tab2){ref-type="table"}). Table 1Components of the Trial group's diet Table 2Menu plan and protocol of the hospital meals for the mealworm and control groupsMealworm groupControl groupStep 1MenuNutrientEnergyProteinCarbohydrateFatCarbohydrate-based liquid diet, Mealworm jelly580 kcal13 g114 g8 gCarbohydrate-based liquid diet, Juice450 kcal16 g84 g6 gStep 2MenuNutrientEnergyProteinCarbohydrateFatMealworm soup, Mealworm shake with berry,Protein-fortified gelatin1220 kcal50 g180 g34 gCarbohydrate-based liquid diet, Thin low-fat soup, Soybean milk, Protein-fortified gelatin1240 kcal43 g180 g39 gStep 3MenuNutrientEnergyProteinCarbohydrateFatDeluxe rice porridge with soft side dishes,ONS1)-based mealworm drink,Mealworm tea-confectionery1629 kcal81 g225 g45 gRice porridge with soft side dishes1600 kcal75 g235 g40 gProtocolThe doctor prescribes Step 1 diet (clear liquid diet) as the first meal after surgery. Patients eat this diet for 2--3 meals. As the next meal, the doctor prescribes Step 2 diet (full liquid diet). Patients eat this diet for 2--3 meals. If the diet transition goes smoothly, the doctor prescribes Step 3 diet (soft diet). Patients eat this diet until discharge. The doctor prescribes hospital meal intake. Depending on the patient's condition, the steps for consuming the diet could be adjusted. The dietitian surveys the dietary intake every day until discharge. If there is a meal-related side effect, it is reported to the doctor.

### Control intervention {#Sec12}

Patients receiving dietary supplementation with grainpowder after pancreatectomy and hepatectomy will be given grainpowder for their hospitalization period and 2 months after discharge. The grainpowder include 23 g of carbohydrate, 2.9 g of protein and 0.5 g of fat, 106 kcal per 30 g. Group A will receive the grainpowder on postoperative day 7. And group B and C will receive grainpowder in the same dose as trial group's mealworms at the start of diet at postoperative 2 days (Table [3](#Tab3){ref-type="table"}). Table 3Components of the Control group's diet

### Outcome measures {#Sec13}

The primary outcome is the body cell mass index as measured by body composition (Inbody S-10 (Biospace, Seoul, Korea)). The secondary outcome measures are as follows: nutritional index (weight, soft lean mass, fat free mass, fat mass, PG-SGA \[Scored Patient-Generated Subjective Global Assessment\]) and immune function test (that assesses T cells, B cells, cytokines). We will confirm changes in immune cells through FACS (fluorescence-activated cell sorting). Based on the immune assay using blood samples from patients, we will identify changes in several cytokines.

Timeline and recruitment {#Sec14}
------------------------

### Recruitment of study participants {#Sec15}

Once the patients' surgery is confirmed, the research staff will give the study staff a list of the patients. After determining the suitability of the patient, the study staff will assign the patient to the test or control group in a randomized sequence in the order in which they are enrolled. In addition, they will be assigned in a double-blinded manner.

### Randomization {#Sec16}

The researchers will select patients after obtaining consent. Randomization will take place via an allocation randomization system 2 days before the surgery, which will be directed by our department. Patients will be randomized to one of the treatment groups in a 1:1 ratio. After consent for study enrollment is obtained, the randomization process will be applied to identify the next allotment. The surgeons will be blind to the allotment throughout the enrollment process.

### Blinding {#Sec17}

Patients and all team members will be blinded to the intervention. Adverse event (AE) and serious adverse event (SAE) need to be reported as soon as they are noted. This will not have any impact on the endpoint assessment of the patient.

### Data management {#Sec18}

The amount of food consumed by the patient daily will be assessed as a diary entry. The researcher collects the bags left over from the patients at the outpatient clinic. Individual participant medical information obtained as a result of this study is considered confidential and disclosure to third parties is prohibited. Blood samples transferred to the laboratory of Gangnam Severance Hospital will be identifiable by unique trial numbers only. Results related to nutrient indicators (Inbody, PG-SGA) will be managed by a Gangnam Severance Nutrition Team. The blood sample associated with the immune function test will be transferred to the lab of the study staff in Gangnam Severance Hospital, which will then undergo FACS (Fluorescence-activated cell sorting).

### Withdrawal and reporting of adverse effects {#Sec19}

If patients wish to voluntarily withdraw from the study, the patient will be asked if they would be given medical care until any AE symptoms resolve or the patient's condition becomes stable.

Patients can quit the trial at any point without the need to give reasons for their decisions. If voluntary withdrawal occurs prior to diet intervention, the patient will not be randomized, and no more trial data will be collected for that patient. Patients can also withdraw from the trial following diet intervention.

### Statistical methodology {#Sec20}

All data will be entered into a single Microsoft Excel spreadsheet with participants identified only by their unique subject number. All entries will be double-checked by another member of the research team. Statistical analysis will be performed using IBM SPSS version 21.0 (IBM Corp; released 2012. IBM SPSS Statistics for Windows Version 21.0. Armonk, NY, USA). The mean difference in nutrient intakes, changes in body measurements, changes in body composition, and PG-SGA scores will be calculated using the Wilcoxon signed rank test and the Mann Whitney test.

### Monitoring and follow-up period {#Sec21}

The research team is responsible for monitoring the study. At 1 week after discharge, the participants are asked whether they are willing to continue ingesting the mealworm. Every 2 weeks after the patients visit their outpatient clinic, the monitoring researcher will check whether they are taking the mealworm regularly. The research team is also responsible for systematically reviewing the causes of withdrawal from the study. Assessment of these changes will be determined 2 months after surgery (Table [4](#Tab4){ref-type="table"}). Table 4Clinical trial timelineStudy periodEnrolmentAllocationPostoperative dayTimepointDay − 2Day − 11760EnrolmentInitial eligibility screening◆Informed consent◆Allocation◆InterventionsMealworm diet◆◆◆Control diet◆◆Assessments1)Anthropometry2)Nutrition index3)Blood test4)Immune function evaluationHeight, weight, BMIBody compositionPG-SGA◆◆◆◆Complete blood countLiver function testRenal function test◆◆◆◆Immune function◆◆◆◆

### Ethical and legal considerations {#Sec22}

The study protocol was approved by the institutional review board at Gangnam Severance Hospital, Yonsei University of Korea (3--2017-0077). The study complies with the Declaration of Helsinki and the principles of Good Clinical Practice.

Discussion {#Sec23}
==========

The aim of this study is to evaluate the effectiveness and improvement of nutritional status and immune function based on the intake of invalid foods in postoperative patients for major surgery (such surgery of the pancreas, bile duct and liver) after an intervention period of 2 months. Nutritional deficiencies are frequent in patients after abdominal surgery. Malnutrition is an important risk factor for developing sarcopenia \[[@CR9]--[@CR12]\]. The decrease in the amount of fat free mass is associated with an increased mortality rate in patients at risk of malnutrition such as surgery and critical illness \[[@CR13]\]. Protein-enhanced diets are known to increase survival in these patients, and therefore, nutritional support using high-protein foods is important \[[@CR14]\]. Based on studies such as these, high protein foods using mealworm are now being used. However, only a few studies have evaluated the enhancement of immune function in patients after intake of high protein foods. In other studies, immune function evaluations were reported \[[@CR15], [@CR16]\]. Early enteral nutrition after esophageal cancer surgery can effectively improve the nutritional status and enhance the immune function \[[@CR15]\] . Some markers of immune function may be useful for distinguishing patients with good or bad prognoses after head and neck cancer surgery by checking the cytokine levels \[[@CR16]\] . However, there are no studies on the effects of long term use (2 months) of high protein mealworm that can be used effectively for nutritional management of patients after surgery. This will be the first study to directly identify the relationship between nutritional status and immune function after surgery.

AE

:   Adverse Event

CT

:   Computed Tomography

EUS

:   Endoscopic Ultrasound

FACS

:   Fluorescence-Activated Cell Sorting

MRI

:   Magnetic Resonance Imaging

PET-CT

:   Positron Emission Tomography

PG-SGA

:   Scored Patient-Generated Subjective Global Assessment

SAE

:   Serious Adverse Event
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